Epeius reports positive results from Phase I/II pancreatic cancer study
Rexin-G was well tolerated and there was no dose-limiting toxicity. At dose level I, three patients achieved stable disease with no tumor progression; and at dose level II,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.